Rights and permissions
About this article
Cite this article
Evidence for dasatinib, nilotinib “too poor” - NICE. Pharmacoecon. Outcomes News 598, 9 (2010). https://doi.org/10.2165/00151234-201005980-00025
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-201005980-00025